Publications by authors named "Tolino Ersilia"

Article Synopsis
  • * A 64-year-old man with a history of hypertension and diabetes developed multiple keratoacanthomas two weeks after his second booster dose, prompting diagnosis through physical and histopathological examinations.
  • * The patient's condition improved significantly with treatment using cemiplimab, suggesting a possible immune-mediated reaction from the vaccine, but further studies are necessary to assess treatment safety and effectiveness.
View Article and Find Full Text PDF

Psoriasis is a chronic inflammatory disease affecting skin and joints characterized by a chronically altered immune and inflammatory response. Several factors occur from the onset to the development of this disease due to different types of cells spatially and temporally localized in the affected area, such as, keratinocytes, macrophages, neutrophils and T helper lymphocytes. This scenario leads to the chronic release of high levels of inflammatory mediators (, IL-17, IL-23, IL-22, TNF-α, S100 proteins, Defensins) and lastly parakeratosis and thickening of the stratum spinosum.

View Article and Find Full Text PDF
Article Synopsis
  • * Biologics, especially IL-17 and IL-23 inhibitors, have been effective in treating psoriatic lesions, including challenging locations.
  • * This case series presents the first real-life data showing the quick and successful treatment of facial psoriasis in six patients using bimekizumab, even though previous studies didn't specifically address facial lesions.
View Article and Find Full Text PDF

Background: Alopecia areata (AA) is a non-scarring disorder characterized by hair loss that greatly affects patients' quality of life and has a chronic, recurring course. This disease is marked by an inflammatory process, mainly on an autoimmune basis primarily regulated by Janus kinase (JAK).

Research Design And Methods: We conducted a retrospective study evaluating the safety of JAKi in a real-world setting in 91 AA patients, with a specific focus on the assessment of infectious events.

View Article and Find Full Text PDF
Article Synopsis
  • - Treating psoriasis must take into account possible complications like latent viral infections and chronic kidney disease, which can affect treatment choices.
  • - A patient with end-stage kidney disease on hemodialysis was successfully treated with bimekizumab, showing an effective response for eight months, marking a first in this scenario.
  • - Research suggests that some psoriasis medications have similar effectiveness and safety in patients with chronic kidney disease compared to those with normal kidney function, but more studies are needed for clearer conclusions regarding bimekizumab.
View Article and Find Full Text PDF

The use of hyaluronic acid (HA) fillers in oncology patients undergoing PET-CT scans is a topic of debate due to potential interference with imaging accuracy. A 54-year-old female, postmelanoma metastasectomy in the parotid region with subsequent facial nerve palsy (FNP), received HA filler injections for facial symmetry and functional restoration. Follow-up PET-CT scans showed no interference or artifacts attributable to HA injection, allowing for accurate imaging results.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the effects of dupilumab exposure during pregnancy in women with atopic dermatitis, focusing on safety and outcomes for both mothers and infants.
  • Researchers analyzed data from 19 hospitals in Italy, identifying 29 pregnant patients who used dupilumab, with the majority reporting unplanned pregnancies and stopping the medication when they learned of their pregnancy.
  • The findings indicated no significant risks associated with dupilumab for adverse pregnancy or neonatal outcomes, suggesting safety for its use in early pregnancy, but further monitoring is recommended for continued use throughout pregnancy.
View Article and Find Full Text PDF
Article Synopsis
  • Dupilumab is an IgG4 monoclonal antibody that blocks IL-4 and IL-13 signaling, key players in type 2 inflammatory diseases.
  • Originally designed for moderate-to-severe atopic dermatitis, it is now used for other conditions like asthma and chronic rhinosinusitis.
  • The review explores off-label uses of dupilumab for diseases like bullous dermatoses and alopecia areata, as well as its potential in cancer treatments involving anti-PD1 therapy.
View Article and Find Full Text PDF

(BCC) is a skin cancer with low local aggressiveness and a low tendency to metastasize. (BSC) represents an aggressive histological subtype of BCC with intermediate features between (SCC) and BCC. Cemiplimab is currently approved as first-line therapy in SCC and second-line therapy in BCC patients who have progressed on or are intolerant of a Hedgehog pathway Inhibitor (HHI).

View Article and Find Full Text PDF

The correlation between health and diet has always been a subject of interest in the field of dermatology and medicine in general. However, studies in the literature are still scarce, and need further investigation in the field of inflammatory skin diseases. In this paper, we report a case of a patient with atopic dermatitis whose complete recovery occurred only after combining dupilumab therapy with a Mediterranean diet regimen.

View Article and Find Full Text PDF

Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months to 11 years in randomized clinical trials. Aim: The aim of this real-life study was to determine the effectiveness in disease control and safety of dupilumab at W52 in moderate-to-severe AD children aged 6-11 years. All data were collected from 36 Italian dermatological or paediatric referral centres.

View Article and Find Full Text PDF

Objectives: The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and predictive factors influencing the patients' treatment persistence.

Material And Methods: This study included adult patients affected by moderate-to-severe AD treated with dupilumab for at least 16 weeks who visited 7 dermatologic outpatient clinics in Lazio, Italy, from January 2019 until August 2021.

Results: A total of 659 adult patients (345 male [52.

View Article and Find Full Text PDF
Article Synopsis
  • A patient was identified with developmental delays and physical anomalies, who also exhibited both HS and psoriatic plaques, likely linked to a genetic microduplication on chromosome 17q21.31.
  • Treatment with adalimumab led to significant improvement, and the case suggests a potential genetic connection between the CRHR1 gene duplication and the development of both psoriatic arthritis and HS in the patient.
View Article and Find Full Text PDF

Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti-interleukin -23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psoriasis, involving primarily upper limbs, elbow, abdomen and knees (PASI 18 - DLQI 22).

View Article and Find Full Text PDF

A wide range of comorbid conditions are associated with psoriasis, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population. Herein, we present a case of a Caucasian 44-years-old man suffering from a severe schizophrenia, who received guselkumab (a human monoclonal antibody targeting the p40 subunit of IL-23) for the treatment of a moderate-to-severe plaque type psoriasis. After 3 months, the patient reached complete resolution of psoriasis without any side effects, maintained at 6 months follow up visit.

View Article and Find Full Text PDF

Monkeypox infection is an emerging problem and a new challenge for modern medicine. With an increasing number of new cases worldwide, new data regarding the clinical manifestations, characteristics of the patients, risk factors and treatment options are coming to light. Knowing more about the disease will allow to elaborate new helpful methods to facilitate its diagnosis.

View Article and Find Full Text PDF

Background: Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biologic therapies. Currently, Psoriasis Area and Severity Index [PASI] and Dermatology Life Quality Index [DLQI] scores are in use to assess the overall severity of pathology.

View Article and Find Full Text PDF